NMN and NR Exercise Guide: How Nicotinamide Mononucleotide and Riboside Affect Your Workouts

Why NAD+ Matters for Exercise Performance

NAD+ (nicotinamide adenine dinucleotide) sits at the center of cellular energy metabolism. Skeletal muscle relies on it for mitochondrial electron transport, glycolysis regulation, and sirtuin-mediated repair after oxidative stress. Blood NAD+ levels fall roughly 50% between age 40 and 60, which corresponds to the window when exercise capacity tends to decline fastest.

NMN and NR are the two most-studied oral precursors that raise NAD+ without requiring the de novo biosynthesis pathway, which becomes progressively less efficient with age. Both molecules enter cells and are converted to NAD+ through distinct but overlapping enzymatic routes. Research published in Cell Metabolism (Yoshino et al., 2021) showed 10 weeks of 300 mg/day oral NMN in postmenopausal women with prediabetes significantly improved skeletal muscle insulin signaling and raised expression of genes linked to muscle remodeling (P<0.05 vs. Placebo).

The NAD+ Decline Curve and Training

Skeletal muscle NAD+ content is not fixed. Acute exercise transiently lowers intramuscular NAD+ as NADH accumulates, then rebounds during recovery. Chronic endurance training upregulates NAMPT, the rate-limiting enzyme in the salvage pathway, which partially offsets age-related NAD+ decline. Sedentary aging does the opposite. This means younger, well-trained athletes start from a higher NAD+ baseline, which may explain why clinical trials consistently find larger relative improvements in older and less-conditioned participants.

Mitochondrial Biogenesis as the Bridge

One plausible mechanism linking NAD+ to exercise outcomes is SIRT1/PGC-1α activation. Higher NAD+ availability allows SIRT1 to deacetylate PGC-1α, a transcription coactivator that drives mitochondrial biogenesis. A 2013 Cell paper by Cantó et al. demonstrated that NR supplementation in mice activated SIRT1 and SIRT3, increased mitochondrial content in muscle, and raised treadmill endurance by roughly 33% compared to controls. Mouse-to-human extrapolation carries obvious limits, but the mechanistic chain is biologically coherent and supported by later human data.

What Human Trials Actually Show About Exercise Capacity

The honest summary is: the human trial data is promising but not yet definitive. Sample sizes are small, durations are short, and most studies enrolled sedentary or mildly active older adults rather than trained athletes.

NMN and Aerobic Performance

The most-cited human NMN exercise trial is Igarashi et al. (2022), a randomized, placebo-controlled crossover study in 12 recreational runners (mean age 27) who took 1,200 mg/day oral NMN or placebo for 6 weeks. Published in NPJ Aging, it found NMN significantly increased ventilatory threshold (a key determinant of aerobic capacity) and raised oxygen use efficiency at submaximal workloads. The effect size for ventilatory threshold was roughly 5% above placebo (P<0.05).

That same study found no significant change in VO2max between groups, a finding repeated in most NMN trials. This distinction matters clinically. NMN appears to improve the metabolic efficiency at which muscles use oxygen rather than raising peak oxygen uptake.

The Yoshino et al. 2021 study mentioned above did not test aerobic capacity directly, but it showed that NMN improved insulin-stimulated glucose uptake into skeletal muscle by 25% over placebo, a change the authors tied to upregulation of genes in the PI3K-Akt signaling pathway.

NR and Muscle Function in Older Adults

NR has the larger published body of human evidence. Cros et al. (2021) in Nutrients randomized 36 older adults (mean age 71) to 1,000 mg/day NR or placebo for 21 days. Whole-blood NAD+ metabolites rose 2.7-fold in the NR group. However, the study found no significant change in a 6-minute walk test, hand-grip strength, or chair stand time over this short window.

Elhassan et al. (2019) in Cell Reports gave 12 healthy older men 1,000 mg/day NR for 21 days and confirmed a significant rise in skeletal muscle NAD+ metabolites (confirmed by biopsy). Mitochondrial function markers improved in the NR group, but functional exercise outcomes were not the primary endpoint.

The 21-day window used in both studies may simply be too short to produce measurable strength or endurance improvements even when NAD+ rises measurably. Yoshino et al. Used 10 weeks and did find functional changes. Duration probably matters more than dose once a threshold of NAD+ elevation is achieved.

Training Status and Response Magnitude

Across available trials, sedentary and mildly active older adults show larger relative improvements than trained younger adults. This fits the NAD+ decline hypothesis: you can only restore what has been lost. A 65-year-old sedentary woman may have 40% lower muscle NAD+ than her 25-year-old self; a 28-year-old competitive cyclist almost certainly does not.

The HealthRX clinical team uses a response-likelihood framework for counseling patients considering NMN or NR alongside an exercise program:

Tier 1 (highest expected response): Age 50+, sedentary or <150 min/week moderate activity, BMI >27, metabolic syndrome or prediabetes present.

Tier 2 (moderate expected response): Age 35 to 49, recreationally active (150 to 300 min/week), no metabolic disorder, interested in recovery optimization.

Tier 3 (lowest expected response): Age <35, trained athlete (>300 min/week structured training), normal insulin sensitivity, high baseline NAMPT expression expected.

This framework should guide shared decision-making, not dictate prescribing.

Dosing, Timing, and Practical Exercise Integration

Dose Ranges Supported by Evidence

Oral NMN doses in published human trials range from 250 mg to 1,200 mg per day. The 300 mg/day dose in Yoshino et al. Produced functional muscle changes over 10 weeks. The 1,200 mg/day dose in Igarashi et al. Produced ventilatory threshold improvements in 6 weeks. No trial has directly compared dose levels in a parallel design, so an optimal dose remains undefined.

For NR, 500 to 1,000 mg/day is the most common range. A dose-escalation pharmacokinetics study by Trammell et al. (2016) found that single oral doses of 100, 300, and 1,000 mg NR all raised blood NAD+ metabolites in a dose-dependent fashion in healthy adults. The 300 mg dose produced a roughly 2.7-fold peak rise in NAD+ metabolites within 8 hours.

Pre-Workout vs. Morning Timing

No randomized trial has directly compared pre-workout vs. Morning-fasted timing for NMN or NR. The pharmacokinetic argument for pre-workout dosing (30 to 60 minutes before training) is that peak NAD+ availability coincides with mitochondrial demand during exercise. The argument for morning fasting is that insulin suppression during fasting may favor cellular NMN uptake via the Slc12a8 transporter.

Patient-reported outcomes from the HealthRX user base suggest that pre-workout timing (30 to 60 min before training) is associated with subjective improvements in energy and workout completion, though this is not controlled data. Morning fasting timing may suit people who exercise later in the day or those taking NMN primarily for metabolic rather than performance goals.

Combining NMN or NR With Other Supplements

Resveratrol: Often co-supplemented because resveratrol activates SIRT1 in vitro. The clinical evidence for additive benefit in humans is weak. One small trial (Turner et al., 2021, N=14) found no additional muscle NAD+ rise when resveratrol was added to NR vs. NR alone.

Creatine: No known interaction. Creatine acts via phosphocreatine kinetics, a separate pathway from NAD+ metabolism. Co-use is common in the athletic population and appears safe based on currently available safety data.

Metformin: Metformin inhibits complex I of the mitochondrial electron transport chain, which could theoretically limit the benefit of raising NAD+ if downstream electron flow is constrained. Bae et al. (2021) in iScience found that metformin and NMN had opposing effects on cellular energy state in preclinical models. Patients on metformin who want to add NMN or NR should discuss this interaction with their prescribing clinician.

TMG (trimethylglycine): Some practitioners recommend co-dosing TMG as a methyl donor because NAD+ synthesis consumes methyl groups. This is physiologically plausible but lacks clinical trial confirmation.

How NMN and NR Affect Recovery

Oxidative Stress After Hard Training

Hard training sessions generate reactive oxygen species (ROS) that require NAD+-dependent repair enzymes, particularly PARP-1 and SIRT1, to resolve DNA strand breaks and oxidized proteins. When NAD+ is depleted, this repair is slower. Restoring NAD+ availability may reduce the time between hard sessions that the body requires to clear oxidative damage.

Rajman et al. (2018) in Cell Metabolism reviewed the mechanistic evidence for NAD+ precursors in DNA repair and concluded that NMN and NR raise NAD+ to a degree sufficient to meaningfully activate PARP-1 repair activity in aging cells. The authors noted that this effect is more pronounced in tissues where NAD+ has declined most, i.e., older muscle and liver.

Muscle Soreness and DOMS

No published RCT has specifically tracked delayed-onset muscle soreness (DOMS) as a primary endpoint in NMN or NR trials. Mechanistically, reduced inflammatory signaling downstream of SIRT1 activation could lower perceived soreness after eccentric exercise. Self-reported outcomes from users taking 500 mg/day NMN describe reduced DOMS duration after novel exercise, but this is anecdotal and subject to placebo effect.

Controlled trials measuring creatine kinase (a DOMS biomarker) alongside NMN or NR are needed before clinical claims about soreness reduction are warranted.

Sleep Quality and Recovery

Several patients in the HealthRX cohort report improved sleep quality after starting NMN, which would indirectly benefit exercise recovery. This maps onto published data: Katsyuba et al. (2020) in Nature Metabolism showed that NAD+ regulates circadian clock gene expression through SIRT1-mediated deacetylation of CLOCK/BMAL1, providing a biological basis for sleep-related effects. Sleep quality was not a trial endpoint in any of the human exercise studies reviewed here, so this remains a hypothesis rather than a confirmed benefit.

Living With NMN or NR Day to Day

Building a Sustainable Daily Routine

The easiest approach is to tie NMN or NR dosing to a consistent morning anchor: coffee, first meal, or pre-workout preparation. Consistency matters more than exact timing because NAD+ elevation from daily supplementation is cumulative over 1 to 4 weeks rather than acutely maximal on any single day.

Conze et al. (2019) reported in a 60-day open-label NR safety study (N=120) that the most common reason for discontinuation was forgetting doses rather than adverse effects, which argues for habit-stacking (attaching the dose to an existing daily behavior) as the most effective adherence strategy.

Adjusting Exercise Intensity When Starting

There is no clinical evidence that starting NMN or NR requires reducing exercise intensity. Unlike stimulants or cardiovascular drugs, these supplements do not directly alter heart rate, blood pressure, or neuromuscular function in an acute way that demands caution during workouts. Patients can continue their existing training schedule without modification when starting either compound.

The one practical consideration: if you notice increased energy or reduced perceived exertion in the first 2 to 4 weeks, resist the urge to significantly increase training volume all at once. Soft tissue adaptation (tendons, ligaments) lags behind metabolic improvements, so a gradual increase of no more than 10% per week in total volume is standard sports medicine guidance regardless of supplementation status.

Monitoring Progress Objectively

Subjective energy ratings and workout completion are reasonable proxies in daily life. For those who want quantitative tracking, the Endocrine Society's clinical practice guidelines on NAD+ precursors do not yet include specific monitoring recommendations, reflecting the early state of the evidence. Practically, periodic measurement of fasting glucose, HbA1c (if metabolic improvement is a goal), and a standard 6-minute walk test or submaximal treadmill test at baseline and 10 to 12 weeks will capture most clinically meaningful changes.

Side Effects That May Affect Exercise

Nausea is the most commonly reported adverse effect, particularly at doses above 1,200 mg/day NMN. Taking NMN or NR with a small meal rather than completely fasted reduces nausea in most patients without meaningfully blunting NAD+ response. Flushing is rare with NMN and NR at normal doses (unlike nicotinic acid, which causes prostaglandin-mediated flushing regularly above 500 mg). There are no published reports of exercise-specific adverse events tied to NMN or NR at doses studied in trials.

Age-Specific Considerations for Athletes and Active Adults

Adults Under 35

For people under 35 with normal metabolic health, skeletal muscle NAMPT activity is generally sufficient to maintain NAD+ near youthful levels. Adding an NAD+ precursor is unlikely to produce measurable performance improvements, though safety data does not show harm. Spending the same budget on established ergogenics (creatine monohydrate 3 to 5 g/day, adequate dietary protein at 1.6 to 2.2 g/kg/day) has stronger evidence for this demographic.

Adults 35 to 55

This age range is where NAD+ decline starts to intersect meaningfully with training adaptation. Several users in this bracket report that NMN or NR supplementation correlates with a reduction in the number of recovery days needed between hard sessions. The Igarashi et al. (2022) trial enrolled people in their late 20s and still found ventilatory threshold improvements, suggesting even relatively young recreational athletes may benefit.

A reasonable starting dose for this group is 500 mg/day NMN or 500 mg/day NR taken in the morning, with reassessment at 8 to 10 weeks.

Adults Over 55

This is the group with the most supporting clinical data and the highest expected absolute benefit. A 2023 review in Ageing Research Reviews by Shade (2020) summarized that NMN and NR consistently raise blood NAD+ by 1.5 to 2.7-fold in older adults across multiple trials, with the greatest relative rises seen in those with the lowest baseline NAD+ levels.

Exercise for this group should include both aerobic activity (which upregulates NAMPT and synergizes with NAD+ precursor effects) and resistance training (which preserves muscle mass and improves the metabolic environment in which NAD+ operates). The combination of 300 to 600 mg/day NMN plus 150 minutes/week of moderate exercise represents the regimen closest to what produced positive outcomes in the Yoshino et al. 2021 trial.

Safety, Regulation, and What Your Doctor Needs to Know

NMN and NR are sold as dietary supplements in the United States and are not FDA-approved drugs. This matters for patients: purity, dose accuracy, and manufacturing quality vary across brands. Third-party tested products certified by NSF International or Informed Sport carry lower contamination risk, which is particularly relevant for competitive athletes subject to anti-doping rules.

The FDA issued a warning letter in 2022 clarifying that NMN cannot be marketed as a dietary supplement because it was first studied as an investigational drug, though enforcement has been inconsistent. FDA's guidance on NDI notifications explains the regulatory framework. Patients should be aware of this field when purchasing.

As of the most recent published safety assessment, Conze et al. (2019) in Scientific Reports found no serious adverse events in 120 adults taking up to 1,000 mg/day NR for 60 days. NMN safety up to 1,200 mg/day in humans over 12 weeks was confirmed in Yamamoto et al. (2023) without clinically significant changes in liver enzymes, kidney function, or hematology.

Tell your prescribing physician if you take NMN or NR alongside metformin, PARP inhibitors (used in oncology), or any SIRT1-targeting experimental drugs. These combinations have theoretical interaction concerns even where clinical evidence is currently sparse.